AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26248813 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 23594265 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based echocardiography resource
Number of subjects: 28
Study 23594265 — intervention group
Group type: COMPARATOR
Intervention: Traditional methods (non-internet group)
Number of subjects: 28
Study 21971704 — intervention group
Group type: EXPERIMENTAL
Intervention: Duke Activity Status Index (DASI) questionnaire
Number of subjects: 200
Study 21971704 — intervention group
Group type: EXPERIMENTAL
Intervention: Duke Activity Status Index (DASI) questionnaire with age consideration
Number of subjects: 200
Study 19522862 — intervention group
Group type: EXPERIMENTAL
Intervention: Male circumcision
Number of subjects: 455
Study 16918719 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine (100 mg)
Number of subjects: 8
Study 16918719 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine (100 mg) and Erythromycin (1500 mg)
Number of subjects: 8
Study 16918719 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 15546255 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy of thymalfasin (thymosin-alpha 1) and peginterferon alfa-2a
Number of subjects: 0
Study 15546255 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 0
Study 11342732 — intervention group
Group type: EXPERIMENTAL
Intervention: Heating and humidifying CO2
Number of subjects: 40
Study 11342732 — intervention group
Group type: COMPARATOR
Intervention: Awake laparoscopy without heating and humidifying CO2
Number of subjects: 40
Study 9791292 — intervention group
Group type: EXPERIMENTAL
Intervention: Interplak toothbrush
Number of subjects: 56
Study 9791292 — intervention group
Group type: COMPARATOR
Intervention: Manual toothbrush
Number of subjects: 56
Study 30274649 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdiagnostic Sleep and Circadian Intervention for Youth (TranS‐C)
Number of subjects: 176
Study 30274649 — intervention group
Group type: COMPARATOR
Intervention: Psychoeducation (PE)
Number of subjects: 176
Study 26940686 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine maintenance therapy
Number of subjects: 274
Study 26940686 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 274
Study 25391864 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 kV, Iodixanol (320 mgI/ml), SAFIRE
Number of subjects: 135
Study 25391864 — intervention group
Group type: COMPARATOR
Intervention: 80 kV, Iopamidol (370 mgI/ml), SAFIRE
Number of subjects: 135
Study 25391864 — intervention group
Group type: COMPARATOR
Intervention: 100 kV, Iodixanol, FBP
Number of subjects: 135
Study 23461283 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine
Number of subjects: 323
Study 23461283 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide
Number of subjects: 323
Study 23461283 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost
Number of subjects: 323
Study 23461283 — intervention group
Group type: EXPERIMENTAL
Intervention: Travoprost
Number of subjects: 323
Study 23461283 — intervention group
Group type: EXPERIMENTAL
Intervention: Brinzolamide
Number of subjects: 323
Study 23461283 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol
Number of subjects: 323
Study 23461283 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimatoprost
Number of subjects: 323
Study 23461283 — intervention group
Group type: COMPARATOR
Intervention: No IOP-lowering medication
Number of subjects: 323
Study 19362280 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-item search task
Number of subjects: 0
Study 19362280 — intervention group
Group type: EXPERIMENTAL
Intervention: Parallel search task
Number of subjects: 0
Study 19362280 — intervention group
Group type: EXPERIMENTAL
Intervention: Serial search task
Number of subjects: 0
Study 17049662 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-year lifestyle intervention by Certified Expert Nurse (CEN)
Number of subjects: 134
Study 17049662 — intervention group
Group type: COMPARATOR
Intervention: Usual care group
Number of subjects: 134
Study 14740283 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa
Number of subjects: 314
Study 14740283 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 314
Study 11484098 — intervention group
Group type: EXPERIMENTAL
Intervention: HEBP (200 mg per day for 2 weeks, followed by 2 g calcium lactate and 0.5 microg alphacalcidol per day for 10 weeks, repeated for 2 years)
Number of subjects: 40
Study 11484098 — intervention group
Group type: COMPARATOR
Intervention: Ca. D (2 g calcium lactate and 0.5 microg alphacalcidol per day for 2 years)
Number of subjects: 40
Study 9710840 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula PO (palm olein 45%)
Number of subjects: 10
Study 9710840 — intervention group
Group type: COMPARATOR
Intervention: Formula HOS (high-oleic safflower oil 42%)
Number of subjects: 10
Study 7989978 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter arterial chemoembolization therapy using iodized oil (Lipiodol) before PET study
Number of subjects: 30
Study 7989978 — intervention group
Group type: EXPERIMENTAL
Intervention: FDG-PET
Number of subjects: 30
Study 2742469 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzocaine spray
Number of subjects: 0
Study 2742469 — intervention group
Group type: EXPERIMENTAL
Intervention: Air spray
Number of subjects: 0
Study 2742469 — intervention group
Group type: COMPARATOR
Intervention: Placebo (air spray)
Number of subjects: 0
Study 1234015 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiorytmin Retard (sustained-release preparation)
Number of subjects: 0
Study 1234015 — intervention group
Group type: COMPARATOR
Intervention: Pronestyl (conventional formulation)
Number of subjects: 0
Study 30815685 — intervention group
Group type: EXPERIMENTAL
Intervention: HCMV glycoprotein B/MF59 vaccine
Number of subjects: 0
Study 28383466 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle decompression at the 2nd intercostal space (2MCL)
Number of subjects: 7
Study 28383466 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle decompression at the 5th intercostal space along the anterior axillary line (5AAL)
Number of subjects: 7
Study 28383466 — intervention group
Group type: COMPARATOR
Intervention: Various devices used for decompression (14G AC, 10G AC, mVN, LT)
Number of subjects: 7
Study 28383466 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracoscopy evaluation
Number of subjects: 7
Study 26505753 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood- plus liver-stage drugs (chloroquine [CQ], 3 d; artemether-lumefantrine [AL], 3 d; primaquine [PQ], 20 d, 10 mg/kg total dose)
Number of subjects: 504
Study 26505753 — intervention group
Group type: COMPARATOR
Intervention: Blood-stage drugs only (CQ, 3 d; AL, 3 d; placebo [PL], 20 d)
Number of subjects: 504
Study 23102821 — intervention group
Group type: COMPARATOR
Intervention: Ongoing medication algorithm alone (medication only)
Number of subjects: 808
Study 23102821 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication plus cognitive behavioral analysis system of psychotherapy
Number of subjects: 808
Study 23102821 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication plus brief supportive psychotherapy
Number of subjects: 808
Study 22108748 — intervention group
Group type: EXPERIMENTAL
Intervention: Norwegian version of the fecal incontinence quality-of-life scale (FIQLS)
Number of subjects: 76
Study 18973027 — intervention group
Group type: EXPERIMENTAL
Intervention: Gancao Fuzi Decoction
Number of subjects: 100
Study 18973027 — intervention group
Group type: COMPARATOR
Intervention: Votalin sustained released tablets
Number of subjects: 100
Study 17384514 — intervention group
Group type: COMPARATOR
Intervention: Open TME
Number of subjects: 74
Study 17384514 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic TME
Number of subjects: 74
Study 14762035 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose formulation (n = 1827): 25 mg of pyridoxine, 0.4 mg of cobalamin, and 2.5 mg of folic acid
Number of subjects: 3680
Study 14762035 — intervention group
Group type: COMPARATOR
Intervention: Low-dose formulation (n = 1853): 200 microg of pyridoxine, 6 microg of cobalamin, and 20 microg of folic acid
Number of subjects: 3680
Study 14762035 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose formulation
Number of subjects: 3680
Study 14762035 — intervention group
Group type: COMPARATOR
Intervention: Low-dose formulation
Number of subjects: 3680
Study 12594878 — intervention group
Group type: EXPERIMENTAL
Intervention: Linezolid 600 mg twice daily (intravenously or orally)
Number of subjects: 0
Study 9039837 — intervention group
Group type: EXPERIMENTAL
Intervention: 55 mmol/L glucose solution
Number of subjects: 6
Study 9039837 — intervention group
Group type: EXPERIMENTAL
Intervention: 110 mmol/L glucose solution
Number of subjects: 6
Study 9039837 — intervention group
Group type: COMPARATOR
Intervention: Glucose-free solution
Number of subjects: 6
Study 7897947 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression of the ipsilateral common carotid artery
Number of subjects: 58
Study 3228775 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% cyclopentolate plus 0.5% tropicamide
Number of subjects: 20
Study 3228775 — intervention group
Group type: COMPARATOR
Intervention: 1% cyclopentolate alone
Number of subjects: 20
Study 3228775 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination drop
Number of subjects: 20
Study 31095868 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-mL syringe with 30-G needle
Number of subjects: 20
Study 31095868 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-mL syringe with 30-G needle
Number of subjects: 20
Study 28222701 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium (0.6 mg.kg‐1)
Number of subjects: 15
Study 28222701 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 15
Study 26174323 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Recovery (ACT)
Number of subjects: 21
Study 26174323 — intervention group
Group type: COMPARATOR
Intervention: Cold Water Immersion (CWI)
Number of subjects: 21
Study 23638141 — intervention group
Group type: EXPERIMENTAL
Intervention: Titration at 0.5 μg/ml
Number of subjects: 144
Study 23638141 — intervention group
Group type: EXPERIMENTAL
Intervention: Titration at 0.2 μg/ml
Number of subjects: 144
Study 23638141 — intervention group
Group type: EXPERIMENTAL
Intervention: Titration at 0.1 μg/ml
Number of subjects: 144
Study 23638141 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction Ce of propofol at 0.5 μg/ml
Number of subjects: 144
Study 23638141 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction Ce of propofol at 0.2 μg/ml
Number of subjects: 144
Study 23638141 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction Ce of propofol at 0.1 μg/ml
Number of subjects: 144
Study 23638141 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjustment frequency at 0.1 μg/ml
Number of subjects: 144
Study 23638141 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients requiring no further adjustment
Number of subjects: 144
Study 23638141 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients requiring at least one adjustment
Number of subjects: 144
Study 22046693 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoflas
Number of subjects: 45
Study 22046693 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc oxide eugenol
Number of subjects: 45
Study 22046693 — intervention group
Group type: EXPERIMENTAL
Intervention: Metapex
Number of subjects: 45
Study 19185677 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormonal method
Number of subjects: 192
Study 19185677 — intervention group
Group type: EXPERIMENTAL
Intervention: Male condom
Number of subjects: 192
Study 19185677 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional method
Number of subjects: 192
Study 19185677 — intervention group
Group type: EXPERIMENTAL
Intervention: No method
Number of subjects: 192
Study 19185677 — intervention group
Group type: EXPERIMENTAL
Intervention: Unmet need for contraception
Number of subjects: 192
Study 19185677 — intervention group
Group type: EXPERIMENTAL
Intervention: Low knowledge of contraceptive effectiveness
Number of subjects: 192
Study 19185677 — intervention group
Group type: EXPERIMENTAL
Intervention: Low self‐efficacy to negotiate condom use
Number of subjects: 192
Study 17259914 — intervention group
Group type: EXPERIMENTAL
Intervention: Active stimulation group
Number of subjects: 20
Study 17259914 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation group
Number of subjects: 20
Study 14693162 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGM‐CSF (2.8 microg/kg body weight)
Number of subjects: 16
Study 14693162 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 16
Study 14693162 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 16
Study 11194114 — intervention group
Group type: EXPERIMENTAL
Intervention: 70% CHO diet during high-intensity exercise trial
Number of subjects: 5
Study 11194114 — intervention group
Group type: COMPARATOR
Intervention: 45% CHO diet during high-intensity exercise trial
Number of subjects: 5
Study 11194114 — intervention group
Group type: EXPERIMENTAL
Intervention: Both trials (70% CHO and 45% CHO)
Number of subjects: 5
Study 9605087 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygenated blood cardioplegia
Number of subjects: 61
Study 9605087 — intervention group
Group type: COMPARATOR
Intervention: Oxygenated crystalloid cardioplegia
Number of subjects: 61
Study 8155440 — intervention group
Group type: EXPERIMENTAL
Intervention: Supinated forearm with wrist extended (group A)
Number of subjects: 40
Study 8155440 — intervention group
Group type: COMPARATOR
Intervention: Hand strapped into a fist and laid supine (group B)
Number of subjects: 40
Study 8155440 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaphoid pressure applied to all patients
Number of subjects: 40
Study 3293726 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% levobunolol hydrochloride
Number of subjects: 27
Study 3293726 — intervention group
Group type: COMPARATOR
Intervention: 0.5% timolol maleate
Number of subjects: 27
Study 31594032 — intervention group
Group type: EXPERIMENTAL
Intervention: MaxCASTcodes 5 and 6 (dentine and pulpally involved cavities)
Number of subjects: 308
Study 31594032 — intervention group
Group type: COMPARATOR
Intervention: MaxCASTcode 3 (enamel carious lesion)
Number of subjects: 308
Study 29072676 — intervention group
Group type: EXPERIMENTAL
Intervention: Sprinting protocol (gradually increasing spontaneous breathing time off CPAP)
Number of subjects: 86
Study 29072676 — intervention group
Group type: COMPARATOR
Intervention: Non-sprinting protocol (weaning pressure down)
Number of subjects: 86
Study 29072676 — intervention group
Group type: EXPERIMENTAL
Intervention: Sprinting protocol
Number of subjects: 86
Study 29072676 — intervention group
Group type: COMPARATOR
Intervention: Non-sprinting protocol
Number of subjects: 86
Study 26864356 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein (22 g), essential amino acids (10.9 g, including 4 g leucine), and vitamin D [2.5 μg (100 IU)] with physical activity
Number of subjects: 130
Study 26864356 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein, essential amino acids, and vitamin D with physical activity
Number of subjects: 130
Study 25270680 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed-release dimethyl fumarate (DMF) 240 mg twice daily (BID)
Number of subjects: 392
Study 25270680 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed-release dimethyl fumarate (DMF) 240 mg three times daily (TID)
Number of subjects: 392
Study 25270680 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 392
Study 22459680 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg
Number of subjects: 81
Study 22459680 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 20814119 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 600 mg twice daily for 10 days
Number of subjects: 14
Study 20814119 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 20814119 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 14
Study 17986904 — intervention group
Group type: EXPERIMENTAL
Intervention: 6.4% carbohydrate-electrolyte solution (CHO-E)
Number of subjects: 16
Study 17986904 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 16
Study 15580472 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of continence training (CT) with transanal or perineal electrical stimulation
Number of subjects: 180
Study 15580472 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapeutic pelvic floor training alone
Number of subjects: 180
Study 15580472 — intervention group
Group type: EXPERIMENTAL
Intervention: Perineal electrical stimulation
Number of subjects: 180
Study 15580472 — intervention group
Group type: EXPERIMENTAL
Intervention: Transanal electrical stimulation
Number of subjects: 180
Study 12440337 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal suppositoria of 100 mg Metronidazole (Arilin rapid) for 2 days
Number of subjects: 45
Study 12440337 — intervention group
Group type: EXPERIMENTAL
Intervention: Arilin rapid x 1 glob./2 days followed by vaginal tablets containing lactic acid x 1 glob. for 7 days
Number of subjects: 45
Study 12440337 — intervention group
Group type: COMPARATOR
Intervention: Placebo therapy (shampoo Dercome Femme containing lactic acid for external application)
Number of subjects: 45
Study 9505164 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula with 7 g of sugar beet fiber
Number of subjects: 15
Study 9505164 — intervention group
Group type: COMPARATOR
Intervention: Formula without sugar beet fiber
Number of subjects: 15
Study 7872217 — intervention group
Group type: EXPERIMENTAL
Intervention: Caprenin-rich diet (Cap)
Number of subjects: 24
Study 7872217 — intervention group
Group type: COMPARATOR
Intervention: Baseline diet enriched in palm oil/palm-kernel oil (PO/PKO)
Number of subjects: 24
Study 2205342 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin converting enzyme inhibitors added to digoxin and diuretics
Number of subjects: 0
Study 2205342 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 293141 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral and smoked delta-9-tetrahydrocannabinol (THC)
Number of subjects: 15
Study 293141 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 293141 — intervention group
Group type: EXPERIMENTAL
Intervention: Delta-9-tetrahydrocannabinol (THC)
Number of subjects: 15
Study 293141 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma THC concentrations < 5.0 ng/mL
Number of subjects: 15
Study 293141 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma THC concentrations 5.0 to 10.0 ng/mL
Number of subjects: 15
Study 293141 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma THC concentrations > 10.0 ng/mL
Number of subjects: 15
Study 30861286 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorsal Root Ganglion (DRG) stimulation
Number of subjects: 61
Study 30452127 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon sinus dilation (BSD) plus medical management (MM)
Number of subjects: 59
Study 30452127 — intervention group
Group type: COMPARATOR
Intervention: Medical management (MM) alone
Number of subjects: 59
Study 27973337 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure-mediated dilatation
Number of subjects: 20
Study 27973337 — intervention group
Group type: COMPARATOR
Intervention: Intra-arterial administration of nitroglycerine plus verapamil
Number of subjects: 20
Study 26015372 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC)
Number of subjects: 76
Study 26015372 — intervention group
Group type: COMPARATOR
Intervention: Sham preconditioning
Number of subjects: 76
Study 26015372 — intervention group
Group type: EXPERIMENTAL
Intervention: RIPC in patients with Mehran risk score ≥11
Number of subjects: 76
Study 26015372 — intervention group
Group type: COMPARATOR
Intervention: Sham in patients with Mehran risk score ≥11
Number of subjects: 76
Study 23444283 — intervention group
Group type: EXPERIMENTAL
Intervention: EC‐MPS
Number of subjects: 27
Study 23444283 — intervention group
Group type: EXPERIMENTAL
Intervention: MMF
Number of subjects: 27
Study 21161182 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprepitant (125 mg)
Number of subjects: 32
Study 21161182 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 19276823 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic sinus surgery with polypectomy
Number of subjects: 27
Study 17158228 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (PV) 40‐1680 mg/day, days 1‐8
Number of subjects: 37
Study 17158228 — intervention group
Group type: COMPARATOR
Intervention: Idarubicin (Ida) [12 mg/(M2 x day), days 4‐6] + high‐dose cytarabine (Ara‐C; HDAC) [1.5 g/(M2 x day) by CI, days 4‐7]
Number of subjects: 37
Study 17158228 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (PV)
Number of subjects: 37
Study 17158228 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (PV) + Idarubicin (Ida) + high-dose cytarabine (Ara-C)
Number of subjects: 37
Study 15150303 — intervention group
Group type: EXPERIMENTAL
Intervention: IP regimen (continuous portal vein infusion of 5‐fluorouracil at 500 mg/m2 daily for 7 days)
Number of subjects: 1084
Study 15150303 — intervention group
Group type: COMPARATOR
Intervention: SY regimen (six 28-day courses of systemic leucovorin at 100 mg/m2 daily on days 1-5 followed by systemic bolus 5‐fluorouracil at 370 mg/m2 daily on days 1-5)
Number of subjects: 1084
Study 15150303 — intervention group
Group type: EXPERIMENTAL
Intervention: IP+SY regimen (IP regimen followed by SY regimen)
Number of subjects: 1084
Study 11331171 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen
Number of subjects: 40
Study 11331171 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure stimuli
Number of subjects: 40
Study 9143014 — intervention group
Group type: EXPERIMENTAL
Intervention: CAG repeat number (39‐56, mean 45.4 +/‐ 4.6)
Number of subjects: 23
Study 9143014 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphometric measurements of cross‐sectional areas of the striatum, pallidum, thalamus, amygdala, hippocampus, and cortical grey and white matter
Number of subjects: 23
Study 7945002 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin therapy
Number of subjects: 25
Study 2873173 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotetan 1g iv at induction of anaesthesia
Number of subjects: 100